Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
July 26 2023 - 7:30AM
Business Wire
Company Announces Participation in BTIG Virtual Biotechnology
Conference
Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced
the Company will release its second quarter 2023 financial results
via press release before the market opens on Tuesday, August 8,
2023.
In addition, Dr. Garo Armen, Chairman and CEO of Agenus, will
participate in the following upcoming investor conferences:
- BTIG Virtual Biotechnology Conference 2023 – Fireside
chat presentation will be held virtually on Monday, August 7th,
2023 at 3:00 PM ET.
A replay of the fireside chat from the BTIG conference can be
accessed on the company’s website at
https://investor.agenusbio.com/events-and-presentations following
the event.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and
infectious diseases with a comprehensive pipeline of immunological
agents. The Company’s mission is to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics), and adjuvants
(through SaponiQx). Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or follow us on LinkedIn
and Twitter @agenus_bio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230726366654/en/
Investor Contact Zack Armen
917-362-1370 investors@agenusbio.com
Media Contact 781-674-4784
communications@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024